Linda Moors, PA
Medical · Tucson, AZNPI 1295776912
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,449 of the $122,378 with a category attached, or 65.7%. AstraZeneca accounts for 66.6% of it on its own, with 32 other manufacturers making up the rest. Among medical clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 341 payments — averaging $358.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$82K
- Daiichi Sankyo Inc.$35K
- Hologic Sales And Service, LLC$2K
- Novartis$1K
- Stemline Therapeutics Inc.$1K
- Seagen Inc.$291
- plus $2K from 27 others
What the payments were for
- Consulting fees$7,0456%
- Speaking & faculty fees$80,44966%
- Travel & lodging$25,65721%
- Food & beverage$8,2727%
- Education$2730%
- Other$6821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 178 | $81,548 |
| Daiichi Sankyo Inc. | 87 | $34,866 |
| Hologic Sales And Service, LLC | 4 | $1,678 |
| Novartis | 10 | $1,176 |
| Stemline Therapeutics Inc. | 4 | $1,091 |
| Seagen Inc. | 8 | $291 |
| Pfizer | 7 | $261 |
| Sumitomo Pharma America, Inc. | 5 | $177 |
| AbbVie | 3 | $164 |
| GSK | 1 | $121 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $115 |
| Incyte Corporation | 5 | $108 |
| Gilead | 2 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $96 |
| Ipsen Biopharmaceuticals, Inc | 1 | $91 |
| Pharmacosmos Therapeutics Inc. | 2 | $66 |
| Myovant Sciences Inc. | 3 | $52 |
| Johnson & Johnson | 2 | $40 |
| Legend Biotech USA Inc. | 2 | $36 |
| Genentech USA, Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Caris MPI, Inc. | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Sanofi | 1 | $22 |
| Immunocore Limited | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Mirati Therapeutics, Inc. | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$122,378 in reported general payments places this provider in the 95th percentile of 748 medical providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 15 | $234,390 |
| ImbruvicaIbrutinib | 12 | $196,347 |
| EliquisApixaban | 17 | $26,685 |
| Letrozole | 368 | $10,374 |
| XareltoRivaroxaban | 12 | $6,695 |
| Exemestane | 22 | $2,854 |
| Ibandronate Sodium | 30 | $1,424 |
| Anastrozole | 64 | $1,190 |
| Tamoxifen Citrate | 34 | $1,028 |
| Hydroxyurea | 30 | $1,004 |
| Gabapentin | 33 | $941 |
| Acyclovir | 29 | $879 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 23 | $852 |
| Oxycodone Hcl | 34 | $850 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $261 | $261,07432 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $115 | $196,34712 claims |
| Johnson & JohnsonXarelto | $40 | $6,69512 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $16427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 748 medical providers in Arizona.
Other medical in Tucson
- Danielle WergeTucson$27K
- Darek AndersonTucson$10K
- Carlos AguilarTucson$8K
- Robert CasquejoScottsdale$474K
- Andrew HicksPeoria$460K
- Darren WestScottsdale$206K
- Jamie WystrachScottsdale$79K
- Scott YoungPhoenix$69K
- Scott LightfootPhoenix$61K
- Jennifer KiserPhoenix$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.